mrna-1653
Vaccineexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 4, 2017 (NCT03392389)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human parainfluenza virus 3Immunity, active
Human parainfluenza virus 3 immunity, active
- MetapneumovirusImmunity, active
Metapneumovirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04144348 | Phase 1 | Nov 30, 2019 | Moderna Therapeutics |
| NCT03392389 | Phase 1 | Dec 4, 2017 | Moderna Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Moderna Therapeutics | For profit | 2 | 2 | 1 | 2017 |
1 organizations
Page 1 / 1